A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
about
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
description
clinical trial
@en
klinisch onderzoek
@nl
name
A Phase 1b/2 Study of Rebastin ...... ced or Metastatic Solid Tumors
@en
type
label
A Phase 1b/2 Study of Rebastin ...... ced or Metastatic Solid Tumors
@en
prefLabel
A Phase 1b/2 Study of Rebastin ...... ced or Metastatic Solid Tumors
@en
P6153
P1476
An Open-Label, Multicenter, Ph ...... ced or Metastatic Solid Tumors
@en
P3098
NCT03601897
P4844
P580
2018-09-19T00:00:00Z
P582
2019-06-01T00:00:00Z